John H. Warner

TL;DR: The natural history of HD is described, including the timing of emergence of motor, cognitive and emotional impairments, and the techniques that are used to assess these features, and potential future roles of these biomarkers in clinical trials are reviewed.

TL;DR: Results of a longitudinal receiver operating characteristic (ROC) analysis showed that CAPS had a relatively strong ability to predict individuals who became diagnosed, especially in the first 2 years.

TL;DR: Characterizing progression in Huntington's disease is important for study the natural course and selecting appropriate participants for clinical trials.

TL;DR: In this paper, the authors quantified the direct healthcare costs and major cost drivers among patients with Huntington's disease (HD), by disease stage in commercial and Medicaid databases, and measured over the followup time of each patient with total costs per patient per stage annualized using a patient-year cost approach.

TL;DR: Changes in phosphodiesterase 10A enzyme levels may be a suitable biomarker of disease progression in Huntington's disease.